We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
+214.41%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$55.6M
AUM Growth
+$32M
Cap. Flow
-$1.62M
Cap. Flow %
-2.92%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$882K
2
HLVX
HilleVax
HLVX
+$742K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
1
DELISTED
Tourmaline Bio
TRML
$35.5M 63.76%
741,691
– –
KRRO icon
2
Korro Bio
KRRO
$153M
$17.6M 31.68%
368,085
– –
JSPR icon
3
Jasper Therapeutics
JSPR
$22.9M
$2.21M 3.97%
928,964
– –
KZR
4
DELISTED
Kezar Life Sciences
KZR
$323K 0.58%
82,871
– –
HLVX
5
DELISTED
HilleVax
HLVX
– –
-372,615
Closed -$742K
VTYX
6
DELISTED
Ventyx Biosciences
VTYX
– –
-412,225
Closed -$882K

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q3 2025 Portfolio in Review

As of Q3 2025, Qiming U.S. Ventures Management held 6 positions worth $55.6M, up 136% from $23.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Qiming U.S. Ventures Management's Q3 2025 filing shows 2 closed positions. The largest sale was Ventyx Biosciences, an estimated $882K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management fully exited Ventyx Biosciences in Q3 2025, selling an estimated $882K.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $55.6M portfolio in Q3 2025.
  • Qiming U.S. Ventures Management opened 0 new positions and closed 2 in Q3 2025.
  • Qiming U.S. Ventures Management's portfolio value rose 136% quarter-over-quarter to $55.6M.

Based on Qiming U.S. Ventures Management's 13F filing for Q3 2025, filed 10 Nov 2025.